ALKINDI SPRINKLE
Clinical safety rating: caution
Comprehensive clinical and safety monograph for ALKINDI SPRINKLE (ALKINDI SPRINKLE).
Alkindi Sprinkle (hydrocortisone) is a corticosteroid that binds to the glucocorticoid receptor, leading to modulation of gene expression and suppression of inflammatory mediators, including cytokines, prostaglandins, and leukotrienes. It also has mineralocorticoid activity, promoting sodium retention and potassium excretion.
| Metabolism | Primarily hepatic via reduction and conjugation; major enzymes include 11β-hydroxysteroid dehydrogenase and 5α-reductase; metabolites are glucuronidated and sulfated. |
| Excretion | Renal: 60-70% as 17-hydroxycorticosteroids and 17-ketosteroids; fecal: ~20% (biliary elimination). |
| Half-life | 2-3 hours (plasma cortisol has t1/2 ~1.5-2h; pharmacodynamic effects persist longer due to glucocorticoid receptor binding duration). |
| Protein binding | Corticosteroid-binding globulin (CBG, transcorrin) ~90% bound; albumin ~5%; free fraction 5-10%. |
| Volume of Distribution | 0.3-0.5 L/kg (distributes into total body water; lower Vd compared to cortisol). |
| Bioavailability | Oral: 100% (granules in capsules are converted to hydrocortisone; absolute bioavailability ~96%). |
| Onset of Action | Oral: glucocorticoid effects within 1-2 hours (peak cortisol suppression at ~2h). |
| Duration of Action | 24-36 hours (single dose suppresses adrenal cortisol secretion for approximately 24-36 hours; clinical duration of action is intermediate-acting). |
Hydrocortisone: 10-20 mg orally (as granules) once daily in the morning with food. Dose is individualized based on cortisol levels and clinical response. The typical starting dose for adults is 10-20 mg daily, given as a single morning dose.
| Dosage form | GRANULE |
| Renal impairment | No specific dose adjustment recommended for renal impairment. However, monitor for fluid and electrolyte disturbances in severe renal disease (GFR <30 mL/min) as hydrocortisone can cause sodium retention and potassium loss. |
| Liver impairment | In Child-Pugh class A or B, no dose adjustment typically needed. In severe hepatic impairment (Child-Pugh class C), consider dose reduction by 50% due to reduced cortisol clearance; monitor clinical response and serum cortisol levels. |
| Pediatric use | Weight-based dosing: 8-10 mg/m² body surface area orally once daily (maximum 20 mg/day). Alternatively, 0.3-0.4 mg/kg/day orally once daily. Dose is titrated to clinical response and serum cortisol levels. |
| Geriatric use | No specific dose adjustment required, but lower starting doses may be considered due to increased risk of osteoporosis, glucose intolerance, and hypertension. Monitor blood glucose, bone mineral density, and blood pressure regularly. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for ALKINDI SPRINKLE (ALKINDI SPRINKLE).
| Breastfeeding | Limited human data; prednisolone enters breast milk with M/P ratio approximately 0.1-0.3. Doses ≤40 mg/day are considered compatible with breastfeeding. Monitor infant for adrenal suppression. |
| Teratogenic Risk | First trimester: increased risk of orofacial clefts (odds ratio 3.5-6.2). Second/third trimesters: fetal adrenal suppression, intrauterine growth restriction, oligohydramnios (reversible upon discontinuation). |
| Fetal Monitoring |
■ FDA Black Box Warning
None
| Serious Effects |
["Hypersensitivity to hydrocortisone or any component of the formulation","Systemic fungal infections (except when used as replacement therapy in adrenal insufficiency with concomitant antifungal treatment)","Administration of live or live-attenuated vaccines (e.g., intranasal influenza, MMR, varicella)"]
| Precautions | ["Adrenal suppression with prolonged use or abrupt withdrawal; taper dose gradually.","Increased risk of infections due to immunosuppression; avoid live vaccines.","Exacerbation of systemic fungal infections; use caution in patients with latent tuberculosis or amebiasis.","Monitor for Cushing's syndrome, hyperglycemia, hypertension, and electrolyte imbalances.","May cause growth suppression in pediatric patients; monitor growth in children.","Osteoporosis with long-term use; consider calcium and vitamin D supplementation.","May mask signs of infection or perforation in gastrointestinal disorders.","Use caution in patients with hypothyroidism, cirrhosis, or ocular herpes simplex.","Psychiatric effects including euphoria, insomnia, mood swings, and psychosis."] |
| Food/Dietary |
Loading safety data…
| Maternal blood pressure, glucose, weight; fetal growth ultrasound every 4 weeks from 24 weeks; Doppler if growth restriction suspected; fetal heart rate monitoring in third trimester. |
| Fertility Effects | No known impairment of fertility in males or females at therapeutic doses. Chronic high doses may cause menstrual irregularities and reduce sperm count reversibly. |
| Avoid grapefruit juice during hydrocortisone therapy as it inhibits CYP3A4 metabolism, potentially increasing systemic exposure. No specific food restrictions, but maintain stable intake of high-sodium foods if on high doses due to mineralocorticoid activity. |
| Clinical Pearls | Hydrocortisone granules are for oral use only; do not inject. Administer within 10 minutes of opening capsule to avoid granule hardening. For children unable to swallow whole granules, mix with soft food (e.g., applesauce) but not liquids. Taper dose gradually to avoid adrenal crisis when discontinuing. Monitor for growth suppression in pediatric patients. |
| Patient Advice | Take exactly as prescribed; do not stop suddenly. · Open capsule and sprinkle granules onto a spoonful of soft food (e.g., applesauce, yogurt) and swallow immediately without chewing. · Do not mix with liquids (e.g., water, milk) as granules may not dissolve. · If you miss a dose, take it as soon as remembered unless close to next dose; do not double up. · Carry medical ID indicating glucocorticoid use. · Report signs of infection, unusual stress, or surgery to doctor. |